In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

@article{Krishnan2015InVA,
  title={In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.},
  author={Preethi Sai Krishnan and Jill M Beyer and Neeta Mistry and Gennadiy Koev and Thomas J Reisch and David A DeGoey and Warren M Kati and Andrew L. Campbell and Laura Melody Williams and Wangang Xie and Carolyn M. Setze and Akhteruzzaman Molla and Christine N. Collins and Tami J. Pilot-Matias},
  journal={Antimicrobial agents and chemotherapy},
  year={2015},
  volume={59 2},
  pages={979-87}
}
Ombitasvir (ABT-267) is a hepatitis C virus (HCV) NS5A inhibitor with picomolar potency, pan-genotypic activity, and 50% effective concentrations (EC50s) of 0.82 to 19.3 pM against HCV genotypes 1 to 5 and 366 pM against genotype 6a. Ombitasvir retained these levels of potency against a panel of 69 genotype 1 to 6 chimeric replicons containing the NS5A gene derived from HCV-infected patients, despite the existence of natural sequence diversity within NS5A. In vitro resistance selection… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Similar Papers

Loading similar papers…